APPLICATION
ANDA203720
TYPE
ANDA
ORIGINAL APPROVAL
2018-05-11
LATEST ACTION
2024-12-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
PIPERACILLIN AND TAZOBACTAMPrescription
PIPERACILLIN SODIUM EQ 36GM BASE/VIAL, TAZOBACTAM SODIUM EQ 4.5GM BASE/VIAL · INJECTABLE · INJECTION
Approval history
2024-12-03Labeling · Supplement 13 · standardAP
2024-05-01Labeling · Supplement 11 · standardAP
2024-01-05Labeling · Supplement 9 · standardAP
2024-01-05Labeling · Supplement 8 · standardAP
2021-05-06Labeling · Supplement 3 · standardAP
2018-05-11UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.